Ruthigen, Inc., Subsidiary of Oculus Innovative Sciences, Inc., Appoints Sameer Harish as Chief Financial Officer

Ruthigen, Inc., Subsidiary of Oculus Innovative Sciences, Inc., Appoints
Sameer Harish as Chief Financial Officer

SANTA ROSA, Calif., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Ruthigen, Inc., a
wholly-owned subsidiary of Oculus Innovative Sciences, Inc. (Nasdaq:OCLS),
today announced the appointment of Sameer Harish, a seasoned finance
executive, to the position of chief financial officer effective February 1,
2013. With over 15 years of healthcare industry experience, Mr. Harish brings
a wealth of financial, market research, competitive intelligence and business
strategy expertise to Ruthigen.

"We welcome Sameer's leadership and experience," said Hoji Alimi, chief
executive officer and chairman of Ruthigen. "This is a key appointment to our
executive team at an important time for Ruthigen.We are confident that
Sameer's strategic thinking and analytical background make him the right
person to help us prepare to take Ruthigen public and to drive the company
toward success in the coming years as we look to unlock the full value of our
drug assets."

Prior to joining Ruthigen, Mr. Harish served as principal of Harish Life
Science Advisors since 2011, an independent consulting firm he founded that
provided financial, strategic and market research advisory services to life
science companies. From 2005 until 2011, he served as an equity research
analyst covering medical devices and diagnostics sectors with Needham & Co,
and then subsequently at ThinkEquity. From 2002 through 2005, Mr. Harish
worked as a research analyst at Symmetry Capital, a healthcare-focused hedge
fund, where he guided investments in the medical device, biotechnology and
specialty pharmaceutical companies. Mr. Harish also held research and
laboratory positions at Guidant (now part of Abbott Laboratories) and Synteni
(acquired by Incyte Corporation). Mr. Harish received a bachelor of arts from
the University of California, Berkeley, where he studied molecular and cell
biology with an emphasis in immunology.

"This is a very exciting time to join Ruthigen as the company prepares for its
planned initial public offering later this year," said Mr. Harish. "I believe
my extensive Wall Street experience, in tandem with the talent and experience
of the Ruthigen team, will help accelerate and optimize this planned IPO
process. I believe tremendous opportunity lies ahead for the company, first
with the growth of our unique and differentiated drug candidate in the
surgical space, and later, as we anticipate exploring future applications for
other healthcare opportunities."

About Oculus Innovative Sciences

Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) is a commercial healthcare
company that designs, produces and markets innovative, safe and effective
drugs, devices and nutritional products. Oculus is pioneering innovative
solutions in multiple markets for the dermatology, surgical, wound care and
animal healthcare markets, and has commercialized products in the United
States, Europe, India, China, Mexico and select Middle East countries. The
company's headquarters are in Petaluma, California, with manufacturing
operations in the United States and Latin America. More information can be
found at www.oculusis.com.

About Ruthigen

Ruthigen, Inc. is a wholly owned subsidiary of Oculus Innovative Sciences,
Inc. (Nasdaq:OCLS).Ruthigen focuses on the development of RUT58-60, a drug
candidate intended for accelerating patient discharge post-surgery.RUT58-60
is a new and unique chemical formulation containing twice the concentration of
hypochlorous acid as compared to Oculus Innovative Sciences, Inc.'s
proprietary Microcyn® Technology, along with magnesium and no sodium
hypochlorite. It is specifically designed for internal use, targeting organ
exposure.

RUT58-60 has been formulated based on several clinical studies in
international markets including a 2006 retrospective case-controlled study
involving 40 post-surgical peritonitis patients.The 20 patients in the study
group, who were treated with the preliminary RUT58-60 formulation and saline,
were in the hospital on an average of 22.4 days following surgery, whereas the
control group, which was treated with saline alone, demonstrated a longer
hospital stay on average of 31.9 days. Both groups were treated with systemic
antibiotics.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the commercial and technology progress and future financial performance
of Oculus Innovative Sciences, Inc. and its subsidiaries (the "Company").
These forward-looking statements are identified by the use of words such as
"anticipates," "believes," "expects," "may," "plans," "predicts," "will,"
among others. Forward-looking statements are not guarantees that future
results, plans, intentions or expectations expressed or implied by the Company
will be achieved. Important factors that could cause or contribute such
differences include, such risks that regulatory clinical and guideline
developments may change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals, clinical results may not be replicated in actual patient settings,
protection offered by the Company's patents and patent applications may be
challenged, invalidated or circumvented by its competitors, the available
market for the Company's products will not be as large as expected, the
Company's products will not be able to penetrate one or more targeted markets,
revenues will not be sufficient to fund further development and clinical
studies, the Company may not meet its future capital needs, and its ability to
obtain additional funding, as well as uncertainties relative to varying
product formulations and a multitude of diverse regulatory and marketing
requirements in different countries and municipalities, the uncertainties
associated with effecting a spinoff and initial public offering of a separate
public company, and the discretion of Oculus' Board of Directors to delay or
cancel the spinoff prior to execution, and other risks detailed from time to
time in the Company's filings with the Securities and Exchange Commission
including its annual report on Form 10-K for the year ended March 31, 2012.
The Company disclaims any obligation to update these forward-looking
statements except as required by law.

The Company's press releases contain information about products, which may or
may not be available in any particular country, and if applicable, may have
received approval or market clearance by a governmental regulatory body for
different indications and restrictions in different countries. Each country
has specific laws, regulations and medical practices governing the
communication of medical or other information about medical products. Nothing
herein should be construed as a solicitation or promotion for any product or
for an indication for any product, which is not authorized by the laws and
regulations of the country where the reader resides.

Oculus, Microcyn Technology and Ruthigen are trademarks or registered
trademarks of Oculus Innovative Sciences, Inc. All other trademarks and
service marks are the property of their respective owners.

CONTACT: Media and Investor Contacts:

         Ruthigen Inc.
         Sameer Harish
         Chief Financial Officer
         sharish@ruthigen.com

         Oculus Innovative Sciences, Inc.
         Dan McFadden
         Director of Public and Investor Relations
         (425) 753-2105
         dmcfadden@oculusis.com